CN107603955A - The hybridoma cell strain 7H4 and monoclonal antibody of human cardiac troponin I and application - Google Patents
The hybridoma cell strain 7H4 and monoclonal antibody of human cardiac troponin I and application Download PDFInfo
- Publication number
- CN107603955A CN107603955A CN201710797562.7A CN201710797562A CN107603955A CN 107603955 A CN107603955 A CN 107603955A CN 201710797562 A CN201710797562 A CN 201710797562A CN 107603955 A CN107603955 A CN 107603955A
- Authority
- CN
- China
- Prior art keywords
- ctni
- monoclonal antibody
- hybridoma cell
- cell strain
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses the hybridoma cell strain 7H4 and monoclonal antibody of human cardiac troponin I and application.The hybridoma cell strain 7H4 was stored in China typical culture collection center on 23rd in August in 2017（CCTCC）, deposit number is CCTCC NO：C2017121.The monoclonal antibody 7H4 of hybridoma cell strain 7H4 secretions is the cTnI mouse monoclonal antibodies of a kind of high-affinity, high specific, free cTnI, dimer complex cTnI C, the cTnI of trimer compositions cTnI T tri- kinds of forms of C can be combined, therefore it can be used for detecting cTnI contents in serum, laid the foundation for exploitation quick detection miocardial infarction kit.
Description
Technical field
The present invention relates to cellular immunity technical field, more particularly, to the hybridoma cell strain of human cardiac troponin I
7H4 and monoclonal antibody and application.
Background technology
Cardiac troponin is the systaltic key protein of regulation and control.By cardiac muscle troponin I（cTnI）, myocardium myo calcium egg
White C（cTnC）And serum cardiac troponin T（cTnT）The trimer compositions of three subunit compositions.CTnI is the suppression of actin
Subunit, by the atriphos for suppressing actin（ATPase）Activity carry out the mutual of modulate actin and myosin
Effect.CTnI molecular weight is about 24kDa, is made up of 209 amino acid, is a kind of albumen rich in α spirals, theoretical isoelectric point
For 9.87.TnI（Troponin I）In the presence of three kinds of hypotypes：Skeletal troponin I（sTnI）In fast skeletal muscle type and slow bone be present
Bone flesh type, they have similar molecular weight（20KD）, but 40% difference about be present in amino acid sequence therebetween；3rd
Kind is myocardium type.Cardiac muscle troponin I（cTnI）There is also 40% difference, cTnI ends with the amino acid sequence of skeletal muscle type
31 amino acid more than sTnI end, and cTnI only exists a kind of hypotype in cardiac muscle cell, determines cTnI myocardium thin
Specificity in born of the same parents.The 22nd of cTnI molecules and the 23rd is serine.The two amino acid can be in vivo by albumen
Kinases A phosphorylations, thus in vivo there are four kinds of different phosphate acidification types in cTnI.
Acute myocardial infarction（Acute myocardial infarction, AMI）Be most common angiocardiopathy it
One, it is on the basis of coronary artery pathological changes, blood flow coronarius is drastically reduced or interrupted, and corresponding cardiac muscle occurs serious
And enduringly coronary artery pathological changes caused by acute ischemia, finally cause the ischemic necrosis of cardiac muscle.When being in a bad way, heart
The function of its pump blood can not be exercised again, can cause patient's die by visitation of God.Therefore, the early diagnosis of acute myocardial infarction is pre- for its
Anti- and treatment is very important.CTnI is considered that AMI diagnoses one of best Biological indicators by researcher, because it is in cardiac muscle
Just occur in blood when impaired, and time of occurrence is early, and the duration is long, high specificity, therefore international clinical chemistry alliance
（IFCC）, the biochemical meeting of U.S. clinical（NACB）The authoritative institutions such as branch are examined to be examined cTnI as AMI with Chinese medical
Disconnected " goldstandard ".
In miocardial infarction mark, cTnI is considered as, specificity higher " gold mark " sensitiveer than other marks.
When the cell membrane of cardiac muscle cells is complete, cTnI can not be entered in blood through cell membrane.Only cardiac muscle cells
When impaired, cTnI is discharged into blood rapidly from cardiac muscle cell, starts to raise in 2~8 hours, and peak was reached in 1-2 days, and
And the amount that cTnI still can be measured after 3-8 days is raising, the time that cTnI is maintained in serum in theory more than 10 days, more long
Diagnosis of the diagnostic window phase for miocardial infarction be very important.Research has shown that, normal person and Patients With Myocardial Infarction serum
Middle cTnI critical value is 50pg/mL, and blood level is up to 100~300 μ g/L during morbidity.Most cTnI is in blood
Exist in the form of cTnI-T-C or cTnI-C compounds.Find that cTnI is initially to be discharged into the form of monomer under study for action
In blood, but as Myocardial injury degree increases, in order to prevent cTnI to be degraded, cTnI can exist in the form of compound,
Then due to the influence of various factors, compound resolve into monomer again, should be able to be with same for detecting cTnI antibody
Efficiency identification blood in various complex forms cTnI, and monoclonal antibody resource as famine in the prior art.
The content of the invention
The present invention is in order to overcome above-mentioned deficiency of the prior art, there is provided the hybridoma of one plant of human cardiac troponin I is thin
Born of the same parents' strain 7H4.
It is a further object to provide the monoclonal antibody of above-mentioned hybridoma cell strain 7H4 secretions, monoclonal resists
It is a kind of high-affinity, high specific that body, which is named as human cardiac troponin I monoclonal antibody 7H4, monoclonal antibody 7H4,
CTnI mouse monoclonal antibodies, free cTnI, dimer complex cTnI-C, trimer compositions cTnI- can be combined
The cTnI of tri- kinds of forms of T-C, therefore can be used for detecting cTnI contents in serum, to develop quick detection miocardial infarction kit
Lay the foundation.
Third object of the present invention be to provide human cardiac troponin I monoclonal antibody 7H4 the free cTnI of detection,
Dimer complex cTnI-C, tri- kinds of forms of trimer compositions cTnI-T-C cTnI in application.
To achieve these goals, the present invention is achieved by the following technical programs：
The hybridoma cell strain 7H4, the hybridoma cell strain 7H4 of one plant of human cardiac troponin I were protected on the 23rd in August in 2017
China typical culture collection center be present（CCTCC）, deposit number is CCTCC NO：C2017121.The address of collection
For：Wuhan City, Hubei Province Wuchang District Wuhan University collection.
The human cardiac troponin I monoclonal antibody 7H4 of hybridoma cell strain 7H4 secretions as described above.Autopsy Cases flesh
Calcium protein I monoclonal antibody 7H4 variable region gene includes heavy chain variable region gene and chain variable region gene, monoclonal antibody
7H4 weight chain amino acid sequence is as shown in Figure 2.
Human cardiac troponin I monoclonal antibody 7H4 as described above is in the free cTnI of detection, dimer complex
CTnI-C, tri- kinds of forms of trimer compositions cTnI-T-C cTnI in application.
Monoclonal antibody 7H4 is the monoclonal antibody prepared by using immune cTnI-T-C albumen, and specific preparation method is such as
Under：Balb/c mouse are immunized with holoprotein cTnI-T-C, take the spleen cell of mouse to be merged with myeloma cell, by indirect
ELISA filters out positive hybridoma cell strain, and the miscellaneous of stabilization of antibodies can be secreted by being obtained by limited dilution cloning technology three times
Tumor cell strain is handed over, ascitic type monoclonal antibody is prepared, obtains monoclonal antibody after purification.
Compared with prior art, the present invention has the advantages that：Human cardiac troponin I Dan Ke provided by the invention
Grand antibody 7H4 is the cTnI mouse monoclonal antibodies of a kind of high-affinity, high specific, can combine free cTnI, two
Tri- kinds of dimeric complexes cTnI-C, trimer compositions cTnI-T-C forms cTnI, therefore can be used for detecting in serum
CTnI contents, laid the foundation for exploitation quick detection miocardial infarction kit.
Brief description of the drawings
Fig. 1 is 3 CDR of antibody 7D2 light and weight chains variable region（Complementary determining region）Area.
Fig. 2 is 3 CDR of antibody 7H4 light and weight chains variable region（Complementary determining region）Area.
Fig. 3 is the SDS-PAGE detection figures of antibody 7D2 and 7H4 after purification, wherein, 1 is albumen Marker, and 2 be 7D2, and 3 are
7H4。
Fig. 4 is antibody 7D2 and 7H4 bioactivity ELISA result figures, wherein, figure A is 7D2, and figure B is 7H4.
The affinity constant that Fig. 5 is antibody 7D2 and 7H4 detects ELISA figures, wherein, figure A is 7D2, and figure B is 7H4.
Fig. 6 be antibody 7D2 and 7H4 and cTnI and cTnI-C response diagrams, wherein, figure A is cTnI monomers, and figure B is cTnI-
C compounds.
Fig. 7 is 7D2/HRP-7H4 and 7H4/HRP-7D2 detection curve.
Fig. 8 is 7D2/HRP-7H4 examination criteria curve maps.
Embodiment
The present invention is made with reference to Figure of description and specific embodiment and further being elaborated, the embodiment
It is served only for explaining the present invention, is not intended to limit the scope of the present invention.Test method used in following embodiments is such as without spy
Different explanation, is conventional method；Used material, reagent etc., unless otherwise specified, for the reagent commercially obtained
And material.
Embodiment 1
The preparation of hybridoma cell strain and its monoclonal antibody of secretion, comprises the following steps：
First, antigen
Monoclonal antibody 7D2 is that Balb/c mouse are immunized by using the comlete antigen of 13-24 amino acids on cTnI and BSA couplings
The monoclonal antibody prepared, the preparation method containing the comlete antigen of 13-24 amino acids on cTnI are：Use Discovery
Studio4.0 softwares simulate cTnI-T-C structures, analyze epitope on cTnI subunits, pick out 13-24 amino acids
As epitope antigen.Synthesize 13-24 amino acids on cTnI and be coupled to form comlete antigen with BSA, this step is by peptide in Hangzhou
Company synthesizes.
Monoclonal antibody 7H4 antibody is immunized Balb/c mouse by using whole protein complex cTnI-T-C and prepared
Monoclonal antibody, wherein, cTnI-T-C is bought from Hytest companies of Finland.
2nd, the preparation of hybridoma cell strain：Hybridoma cell strain 7D2 is identical with hybridoma cell strain 7H4 preparation method,
The two is simply specific as follows using different antigen, preparation method：
1st, animal immune
(1) initial immunity：50 μ g antigens are emulsified with isometric complete Freund's adjuvant volume, subcutaneous multi-point injection；
(2) booster immunization：Interval 2 weeks, the amount of antigen same with initial immunity emulsify with isometric incomplete Freund's adjuvant, subcutaneously
Multi-point injection；Its potency is surveyed in blood sampling after being immunized 10 days in the 3-5 times；
(3) 72 hours before fusion, intraperitoneal injection is not added with the antigen 25 μ g of adjuvant.
2nd, cell fusion
(1) myeloma cell SP2/0 raising.Ten days before the fusion SP2/0 cells frozen of recovering, and it is enlarged culture.Take
A part of SP2/0 HAT medium cultures 24 hours, whether observation cell can apoptosis.
(2) feeder cells prepare：Fusion the previous day takes the feeder cells of the Balb/c mouse of health to carry out bed board, and cell is dense
Spend for cell to 1 × 105Individual/mL, per the μ L of hole 100.
(3) SP2/0 preparation.Cell is gently blown down, collected into centrifuge tube, writes down overall solution volume, is mixed simultaneously
Counted after taking the suitably dilution of a small amount of cell.The preparation of splenocyte.The spleen of fusion mouse is taken out, with 1640 basal mediums
Spleen is rinsed, and spleen is in the environment of moistening, grinds spleen, is rinsed and is remained on nook closing member and filter screen with basal medium
Spleen cell, collect lapping liquid, record cumulative volume.Partial mill liquid is taken to be counted.
(4) SP2/0 cells and splenocyte are according to 1:5~1:10 ratio mixes in centrifuge tube, 1000rpm/min centrifugations
7 min, abandon supernatant.1mL PEG preheated in 37 DEG C of water are added, then instill the 1640 of the 15mL having had been warmed up
Basal medium terminating reaction, 1000 rpm/min centrifugation 7min, abandons supernatant, adds HAT complete mediums and is resuspended, and is added per hole
100 μ L, place and cultivated in cell culture incubator, fusion results are observed after five days.
3rd, positive cell screening and cloning
(1) the 5th day observation cell, the hole larger to cell mass carry out changing liquid after fusion, take within the 3rd day cell supernatant to bag
In the plate for having 50ng/ holes antigen, ELISA testing inspections, positive hole needs to change a not good liquor again, detects again every other day, to twice all
The hole of test positive carries out cloning.
(2) cloning is carried out to positive cell with limiting dilution assay, typically carries out cloning three times.
By positive cell screening with after cloning, screening hybridoma cell strain 7D2 and hybridoma cell strain 7H4, two
Person was stored in China typical culture collection center on 23rd respectively at August in 2017（CCTCC）, hybridoma cell strain 7D2 guarantor
It is CCTCC NO to hide numbering：C2017120, hybridoma cell strain 7H4 deposit number are CCTCC NO：C2017121.In preservation
The address of the heart is：Wuhan City, Hubei Province Wuchang District Wuhan University collection.
3rd, the preparation of monoclonal antibody：
Monoclonal antibody 7D2 method is prepared with preparing monoclonal antibody by hybridoma cell strain 7H4 by hybridoma cell strain 7D2
7H4 method is identical, specific as follows：
1st, the preparation of ascitic type antibody
(1) before hybridoma cell strain is injected 7~14 days μ L of BaLb/c mouse peritoneal injections 500 to inoculation incomplete Freund
Adjuvant.
(2) every mouse intraperitoneal injection 2 × 105~1 × 106Individual hybridoma cell strain, volume injected are 500 μ L.General 7
Mouse web portion is substantially swelled after~14 days, and ascites can be extracted when slow in action.
(3) 4 DEG C of the ascites being collected into, 12000 rpm/min are centrifuged 30min, takes supernatant, the degree of packing -20 preserves.
2nd, the purifying of antibody
(1) ammonium sulfate precipitation method：1. by ascites from -20 DEG C of taking-ups, 4 DEG C thaw.2. 4 DEG C of 12000rpm/min centrifuge 30min, take
Supernatant, and record the volume of supernatant.It is stirred 3. ascites is placed under 4 DEG C of frozen water hybird environment, slowly drips while stirring
Add isometric saturated ammonium sulfate solution, it is observed that there is white precipitate generation, continue to stir 15min, 4 DEG C stand overnight.
4. the ascites after saturated ammonium sulphate is centrifuged 30min in 4 DEG C, 7500 rpm, supernatant is abandoned, with 1.5mL PBS（With
0.015M filter membranes filtered）It is resuspended.
(2) salt ion in desalting column protein isolate matter：1. balance：Connect pillar（Prevent air from entering pillar）, with 5 times
The PBS filtered of column volume washes away 20% ethanol for being used to preserve in pillar.2. loading：Speed is slow during loading.3. receive
Sample：Because protein molecule is bigger than the volume of salt ion, protein molecule can not by gap narrow and small in filler in pillar,
It can only first come out in big gap from the side, therefore only receive the sample of first absorption peak.4. balance：With more than 5 times cylinders
The filtered PBS of product rinses pillar.5. preserve：Post is sealed with 20% filtered ethanol, prevents from polluting, 4 DEG C of preservations.
(3) affinity column Protein G separate foreign protein：1. balance：Connect pillar（Prevent air from entering pillar）, use
The PBS filtered of 5 times of column volumes washes away 20% ethanol for being used to preserve in pillar.2. loading：Speed is slow during loading.
3. receive sample：What first absworption peak came out is foreign protein, is not collected.After PBS develops foreign protein, eluent is used
（PH2.7 glycine solutions）Destination protein is eluted, collects albumen, and the elution per 1mL at once when peak value rises
Albumen adds 100 μ L neutralizer（pH9.0Tris-HCL）.4. balance：Pillar is rinsed with the filtered PBS of more than 5 times column volumes.
5. preserve：Post is sealed with 20% filtered ethanol, prevents from polluting, 4 DEG C of preservations.
(4) ultrafiltration：50KD super filter tube is taken, filtered PBS is filled it up with, 5000 rpm/min centrifugation 10min, repeats three
It is secondary.So that film internal and external equilibrium.Add protein sample, 5000 rpm/min centrifugations 10min.The concentrate being collected on collection membrane.
PBS, 5000 rpm/min centrifugation 10min are filled it up with, in triplicate, fills it up with 20% ethanol, 4 DEG C of preservation super filter tubes.
4th, monoclonal antibody performance detection
Extract hybridoma cell strain 7D2 and 7H4 total serum IgE respectively, be cDNA by RNA reverse transcriptions, performing PCR expansion is entered to target gene
Increase, connect pMD-18T carriers, finally import in the Escherichia coli of competence and largely expand, extraction plasmid sends to sequencing.Know list
Clonal antibody 7D2 light and heavy chain amino acid sequence is as shown in figure 1, monoclonal antibody 7H4 light and heavy chain amino acid sequence such as figure
2。
The monoclonal antibody 7D2 and 7H4 that purify to obtain using SDS-PAGE test for identification purity, as a result as shown in Figure 3.
The monoclonal antibody 7D2 and 7H4 that are obtained using ELISA method detection purifying potency, as a result as shown in Figure 4.Utilize ELISA side
Monoclonal antibody 7D2 and 7H4 that method detection purifying obtains affinity constant, as a result as shown in Figure 5.
With the combination situation of the other two kinds of forms of the strain antibody of indirect ELISA test for identification 2 and cTnI：CTnI monomers（Finland
Hytest companies buy）With cTnI-C compounds（Certainly express in laboratory）, can obtain 2 strain antibodies by Fig. 6 can be with cTnI, cTnI-C
With reference to illustrating that 2 strain antibodies in the present invention can identify various forms of cTnI.According to existing research（cTnI-linker-
The prokaryotic expression of TnC fusion proteins and identification, Chinese biological engineering magazine, 2015,35 (4):48-53）Understood with the present embodiment,
7D2,7H4 can with cTnI, cTnI-C or cTnI-T-C occur specific binding reaction, show its can with it is various forms of
CTnI is combined
Embodiment 2
It is capture antibody using monoclonal antibody 7D2,7H4 establishes double-antibody sandwich elisa detection method for detection antibody, can used
In exploitation quick detection miocardial infarction kit.Double-antibodies sandwich ELISA to establish process as follows：
1st, the selection of antibody is matched
(1) it is coated with：Antibody 7D2 is diluted to 2 μ g/mL with coating buffer, adds 100 μ L to 96 hole elisa plates.4 DEG C overnight.Use PBS-T
Buffer solution washs three times, each 3min.
(2) close：It is added to 5% skimmed milk power in elisa plate, 200 μ L is added per hole, 37 DEG C are closed one hour.Use PBS-T
Buffer solution washs three times, each 3min.
(3) antigen cTnI is added：Antigen is diluted to 1000ng/mL, 500ng/mL, 250ng/mL respectively with PBS,
125ng/mL, 62.5ng/mL, 31.25ng/mL, 15.625ng/mL.Add 100 μ L per hole.37 DEG C are incubated one hour.Use PBS-T
Buffer solution washs three times, each 3min.Only plus PBS is as negative control.
(4) marking HRP antibody 7H4：HRP is diluted to suitable multiple with PBS-T buffer solutions（OD in Salmonella450
The corresponding extension rate near 2.0）Per the μ L of hole 100,37 DEG C are incubated one hour.Five times are washed with PBS-T buffer solutions, every time
3min。
(5) develop the color：Add 100 μ LTMB nitrite ions, room temperature lucifuge 10min.
(6) 50 μ L terminate liquids are added per hole.
(7) ELIASA reads 450nm absorption values OD450, analyze data.
2nd, the 7D2 established is capture antibody, and 7H4 is the double-antibody sandwich elisa detection method detection curve of detection antibody
Foundation and detection range establishment：With 0.05 M, pH 9.6 carbonate coating buffer solution dilutes antibody 7D2 to 2 μ g/mL,
Add 100 μ L per hole, 4 DEG C overnight.5% skimmed milk power is closed one hour.Be separately added into various concentrations uses PBS-T buffer solns
The cTnI of Hytest companies of the Finland purchase of dilution is as antigen（1000ng/mL, 500ng/mL, 250ng/mL, 125ng/mL,
62.5ng/mL, 31.25ng/mL, 15.625ng/mL）, per the μ L of hole 50,37 DEG C are incubated 1 hour.100 μ L are separately added into according to 1：
The HRP-7H4 of 2000 dilutions, is incubated one hour.100 μ L nitrite ion TMB are added, are developed the color 10 minutes, add 50 μ L terminate liquids（10%
H2SO4）.ELIASA reads 450nm absorption values OD450, analyze data, standard curve is made according to data.In cTnI concentration
In the range of 30ng/mL~500ng/mL, with the rise of cTnI concentration, ELISA reactions OD450Value rise, cTnI concentration with
OD450Value is linear related, therefore the scope of the detection of this method is：30ng/mL~500ng/mL（Fig. 7）.And depict 7D2
To capture antibody, 7H4 is the standard curve of the double-antibody sandwich elisa detection method of detection antibody（Fig. 8）.
Confirm the scope of detection.
3rd, the detection of clinical sample：30 parts of clinical serum samples are examined with homemade double-antibodies sandwich ELISA
Survey, its positives 22 parts, it is negative 8 parts.Statistic analysis result, positive rate 77.3%, negative recall rate are 100%.
Comparative example 1
It is capture antibody using monoclonal antibody 7H4,7D2 establishes double-antibody sandwich elisa detection method for detection antibody, can used
In exploitation quick detection miocardial infarction kit.Double-antibodies sandwich ELISA to establish process as follows：
1st, the selection of antibody is matched
(1) it is coated with：Antibody 7H4 is diluted to 2 μ g/mL with coating buffer, adds 100 μ L to 96 hole elisa plates.4 DEG C overnight.Use PBS-T
Buffer solution washs three times, each 3min.
(2) close：It is added to 5% skimmed milk power in elisa plate, 200 μ L is added per hole, 37 DEG C are closed one hour.Use PBS-T
Buffer solution washs three times, each 3min.
(3) antigen cTnI is added：Antigen is diluted to 1000ng/mL, 500ng/mL, 250ng/mL respectively with PBS,
125ng/mL, 62.5ng/mL, 31.25ng/mL, 15.625ng/mL.Add 100 μ L per hole.37 DEG C are incubated one hour.Use PBS-T
Buffer solution buffer solution washs three times, each 3min.Only plus PBS is as negative control.
(4) marking HRP antibody 7D2：HRP is diluted to suitable multiple with PBS-T buffer solutions（OD in Salmonella450
The corresponding extension rate near 2.0）Per the μ L of hole 100,37 DEG C are incubated one hour.Five times are washed with PBS-T buffer solutions, every time
3min。
(5) develop the color：Add 100 μ LTMB nitrite ions, room temperature lucifuge 10min.
(6) 50 μ L terminate liquids are added per hole.
(7) ELIASA reads 450nm absorption values OD450, analyze data.
2nd, the 7H4 established is capture antibody, and 7D2 is the double-antibody sandwich elisa detection method detection curve of detection antibody
Foundation and detection range establishment：With coating buffer solution 0.05 M, pH 9.6 carbonate coating buffer solution dilution antibody
7H2 to 2 μ g/mL, 100 μ L are added per hole, 4 DEG C overnight.5% skimmed milk power is closed one hour.Be separately added into various concentrations uses PBS-
The standard antigen cTnI of T buffer solutions dilution（0、15.625、31.25、62.5、125、250、500、1000ng/mL）, per the μ of hole 50
L, 37 DEG C are incubated 1 hour.100 μ L are separately added into according to 1:The HRP-7D2 of 2000 dilutions, is incubated one hour.Add 100 μ L colour developings
Liquid TMB, develop the color 10 minutes, add 50 μ L terminate liquids.ELIASA reads 450nm absorption values OD450, analyze data, it is known that,
In cTnI concentration in the range of 60ng/mL~500ng/mL, with the rise of cTnI concentration, ELISA reactions OD450Value rise,
CTnI concentration and OD450Value is linear related, but the related slope is small.Therefore, the scope of the detection of this method is：60ng/mL~
500ng/mL（Fig. 7）.
Comparing embodiment 2 and comparative example 1 are can be found that：
Respective detection range is determined according to embodiment 7D2/HRP-7H4 and comparative example 7H4/HRP-7D2 detection curve, according to
Figure understands that 7D2/HRP-7H4 detection curve is bigger than 7H4/HRP-7D2 detection curve rates of change, and detection range is wide, high sensitivity.
Claims (3)
1. the hybridoma cell strain 7H4 of one plant of human cardiac troponin I, it is characterised in that the hybridoma cell strain 7H4 in
August is stored in China typical culture collection center on 23rd within 2017（CCTCC）, deposit number is CCTCC NO：C2017121.
2. the human cardiac troponin I monoclonal antibody 7H4 of the hybridoma cell strain 7H4 secretions described in claim 1.
3. the human cardiac troponin I monoclonal antibody 7H4 described in claim 2 is in the free cTnI of detection, dimerization bluk recombination
Thing cTnI-C, tri- kinds of forms of trimer compositions cTnI-T-C cTnI in application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710797562.7A CN107603955B (en) | 2017-09-06 | 2017-09-06 | Human cardiac troponin I hybridoma cell strain 7H4, monoclonal antibody and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710797562.7A CN107603955B (en) | 2017-09-06 | 2017-09-06 | Human cardiac troponin I hybridoma cell strain 7H4, monoclonal antibody and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107603955A true CN107603955A (en) | 2018-01-19 |
| CN107603955B CN107603955B (en) | 2020-06-16 |
Family
ID=61062110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710797562.7A Active CN107603955B (en) | 2017-09-06 | 2017-09-06 | Human cardiac troponin I hybridoma cell strain 7H4, monoclonal antibody and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107603955B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022511323A (en) * | 2018-10-10 | 2022-01-31 | 菲鵬生物股▲フン▼有限公司 | Anti-human myocardial troponin I recombinant antibody |
| JP2022512630A (en) * | 2018-10-10 | 2022-02-07 | ファポン バイオテック インコーポレイテッド | Anti-human myocardial troponin I antibody and its applications |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101935354A (en) * | 2010-07-08 | 2011-01-05 | 温州医学院 | Human cardiac troponin T/ human cardiac troponin I fusion protein |
| CN102725633A (en) * | 2009-12-03 | 2012-10-10 | 雅培制药有限公司 | Assay for diagnosis of cardiac myocyte damage |
| CN103380377A (en) * | 2011-02-25 | 2013-10-30 | 三菱化学美迪恩斯株式会社 | Method for measuring myocardial troponin |
| CN105132383A (en) * | 2015-07-25 | 2015-12-09 | 大庆麦伯康生物技术有限公司 | Hybridomas capable of producing anti-cTnI (cardiac troponini I) monoclonal antibodies |
-
2017
- 2017-09-06 CN CN201710797562.7A patent/CN107603955B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725633A (en) * | 2009-12-03 | 2012-10-10 | 雅培制药有限公司 | Assay for diagnosis of cardiac myocyte damage |
| CN101935354A (en) * | 2010-07-08 | 2011-01-05 | 温州医学院 | Human cardiac troponin T/ human cardiac troponin I fusion protein |
| CN103380377A (en) * | 2011-02-25 | 2013-10-30 | 三菱化学美迪恩斯株式会社 | Method for measuring myocardial troponin |
| CN105132383A (en) * | 2015-07-25 | 2015-12-09 | 大庆麦伯康生物技术有限公司 | Hybridomas capable of producing anti-cTnI (cardiac troponini I) monoclonal antibodies |
Non-Patent Citations (1)
| Title |
|---|
| VLADIMIR L.FILATOV, ET AL.: "Epitope mapping of anti-troponin I monoclonal antibodies", 《BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022511323A (en) * | 2018-10-10 | 2022-01-31 | 菲鵬生物股▲フン▼有限公司 | Anti-human myocardial troponin I recombinant antibody |
| JP2022512630A (en) * | 2018-10-10 | 2022-02-07 | ファポン バイオテック インコーポレイテッド | Anti-human myocardial troponin I antibody and its applications |
| JP7299309B2 (en) | 2018-10-10 | 2023-06-27 | 菲鵬生物股▲フン▼有限公司 | Anti-human cardiac troponin I recombinant antibody |
| JP7307158B2 (en) | 2018-10-10 | 2023-07-11 | ファポン バイオテック インコーポレイテッド | Anti-human cardiac troponin I antibody and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107603955B (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8841419B2 (en) | Hybridoma cell line 10G4 and a monoclonal antibody against the total of aflatoxin B1, B2, G1 and G2 | |
| CN107557345A (en) | The hybridoma cell strain 7D2 and monoclonal antibody of human cardiac troponin I and application | |
| US5702905A (en) | Monoclonal antibody to human ventricular myosin light chains | |
| CN111518176B (en) | Paired antigen for novel coronavirus antibody double-antigen sandwich detection, detection test paper and preparation method thereof | |
| CN107561289B (en) | The double crush syndrome detection kit of human cardiac troponin I | |
| CN102703388B (en) | Anti-human mCRP (monomeric C-reaction protein) monoclonal antibody, hybridoma cell lines and kit | |
| CN112574306B (en) | Adiponectin monoclonal antibody, antibody pair, preparation method and application thereof | |
| CN103045541A (en) | Hybridoma cell strain and monoclonal antibody of anti-heart-type fatty acid-binding protein generated by same | |
| CN108795880A (en) | Generate people's thymidine kinase 1（TK1）The mouse hybridoma cell strain of monoclonal antibody specific and its application | |
| CN107603955A (en) | The hybridoma cell strain 7H4 and monoclonal antibody of human cardiac troponin I and application | |
| CN114316035B (en) | Universal foot-and-mouth disease virus structural protein antibody, preparation method and application thereof | |
| JPH01503331A (en) | Monokine testing method | |
| JP2665503B2 (en) | Monoclonal antibody pair to insulin-like growth factor enables immunoassay for insulin-like growth factor | |
| DE3856004T2 (en) | USE OF MONOCLONAL RECEPTORS AGAINST ONCOPROTEINS FOR MONITORING CANCER THERAPY | |
| CN106957824A (en) | The monoclonal antibody of the anti-human Lp PLA2 albumen of resistance to lipoprotein interference and its application | |
| CN113832132B (en) | Solder tip SVMP protein specific short peptide, solder tip SVMP protein antibody and snake bite detection kit | |
| CN104066749A (en) | Monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof | |
| CN110618270A (en) | Preparation method of reagent for quantitatively determining helicobacter pylori antigen in feces | |
| CN110951703B (en) | Plasmodium vivax lactate dehydrogenase recombinant protein and preparation of monoclonal antibody thereof | |
| CN113956355A (en) | Anti-human Brain Natriuretic Peptide (BNP) rabbit monoclonal antibody and application thereof | |
| CN101796415B (en) | Novel liver cancer marker | |
| CN110903359A (en) | Preparation of campylobacter jejuni recombinant protein and monoclonal antibody thereof | |
| CN108752480B (en) | Immunogen composition, preparation method and application thereof | |
| CN103665113A (en) | Human A beta 42 antigenic determinant polypeptide, human A beta 42 antigen, human A beta 42 antibody, application and kit | |
| CN113930408B (en) | Bamboo leaf green PLA2 protein specific short peptide, anti-bamboo leaf green PLA2 protein antibody and snake bite detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |